UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 4 May 2020, London UK - LSE
Announcement
Publication of Supplementary Prospectus
The following supplementary prospectus dated 30 April 2020 has been
approved by the UK Listing Authority and is available for
viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital
K.K. £20,000,000,000 Euro Medium Term Note
Programme
Copies of the supplementary prospectus and the documents
incorporated by reference within it have been submitted
to submitted to the UK Listing Authority's NSM
submission portal via the Electronic Submission System (ESS). A
copy can be viewed at:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY
PROSPECTUS
Please note that the information contained in
the supplementary prospectus may be addressed to and/or
targeted at persons who are residents of particular countries
(specified in the base prospectus) only and is not intended for use and
should not be relied upon by any person outside these countries
and/or to whom the offer contained in
the base prospectus
is not addressed. Prior to relying on the information
contained in the supplementary prospectus you must ascertain from
the base prospectus
whether or not you are part of the intended addressees of
the information contained therein.
Your right to access this service is conditional upon complying
with the above.
GlaxoSmithKline plc
Registered in England & Wales:
No. 3888792
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
04, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|